Astrocytoma malignant – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:45 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Astrocytoma malignant – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy https://clinicaltrials.eu/trial/vorasidenib-for-patients-with-idh-mutant-grade-2-or-3-astrocytoma-after-completing-first-line-chemoradiotherapy/ Thu, 30 Apr 2026 13:08:21 +0000 https://clinicaltrials.eu/trial/vorasidenib-for-patients-with-idh-mutant-grade-2-or-3-astrocytoma-after-completing-first-line-chemoradiotherapy/ This study involves patients with IDH-mutant grade 2 or 3 astrocytoma, which is a type of brain tumor that has a specific change in its genetic makeup. The treatment being tested is vorasidenib, also known by its code name S95032. This medication comes as a tablet that is taken by mouth. Some patients in the study will receive vorasidenib while others will receive placebo tablets that look the same but contain no active medication. The purpose of this study is to find out if vorasidenib can help slow down tumor growth better than placebo in patients who have completed their first standard treatment with radiation and chemotherapy.

Patients joining this study will have already undergone surgery for their brain tumor and completed their first course of treatment, which includes radiation therapy followed by chemotherapy with either temozolomide or PCV. The study medication or placebo will be given as a maintenance treatment, meaning it is intended to help keep the disease under control after the initial treatment is finished. Patients must start taking the study medication between six and twelve weeks after finishing their last dose of chemotherapy. The study will continue for several years to collect information about how well the treatment works.

During the study, patients will be monitored regularly with brain scans to check if the tumor is growing or staying stable. The main measure of success will be how long patients go without their tumor getting worse, which is called progression-free survival. Doctors will also look at other factors such as overall survival, how patients feel in their daily lives, any side effects from the medication, and how well their brain functions. Safety will be carefully tracked throughout the study to understand any problems that might occur with the treatment.

]]> Study on the Safety of Aminolevulinic Acid with Ultrasound Therapy for Patients with Newly Diagnosed High-Grade Glioma Before Surgery and Standard Treatment https://clinicaltrials.eu/trial/study-on-the-safety-of-aminolevulinic-acid-with-ultrasound-therapy-for-patients-with-newly-diagnosed-high-grade-glioma-before-surgery-and-standard-treatment/ Wed, 29 Apr 2026 14:58:16 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-aminolevulinic-acid-with-ultrasound-therapy-for-patients-with-newly-diagnosed-high-grade-glioma-before-surgery-and-standard-treatment/ This clinical trial is focused on studying a type of fast-growing brain tumor known as high-grade glioma. The trial will explore the safety of a treatment that combines a substance called 5-aminolevulinic acid (5-ALA) with a method called sonodynamic therapy (SDT), which uses ultrasound waves. The treatment is intended for patients who have been newly diagnosed with high-grade glioma and are scheduled for surgery to remove the tumor, followed by standard therapy.

The purpose of the study is to evaluate how safe and tolerable this new treatment is for patients. Participants will receive the treatment in the form of an oral solution, which means it is taken by mouth. The study will monitor patients for any side effects or adverse reactions for a period of 28 days after the treatment is administered. This monitoring will include regular check-ups and tests to ensure the safety of the participants.

Throughout the study, changes in the tumor will be observed using MRI scans, which are imaging tests that help doctors see inside the body. The study will also look at how the treatment affects the tumor at a cellular level. This trial aims to provide valuable information about the potential of 5-ALA combined with SDT as a treatment option for high-grade glioma.

]]>